Xeno Biosciences
Biotechnology, Health Care, Pharmaceutical
Founded in 1/1/15
Somerville, Massachusetts, United States
For Profit
About Xeno Biosciences
Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery. It was founded in 2015 and is headquartered in Somerville, Massachusetts.
Company Metrics
- Employees: 1-10
- Monthly Visits: None
- Tech Stack: None active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: 8750000 USD
- Last Funding: 1500000 USD (Debt Financing)
- Funding Status: Early Stage Venture
Technology Stack
Xeno Biosciences actively uses None products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Pharmaceutical
Headquarters: Somerville, Massachusetts, United States
Employees
- David Beno - Chief Executive Officer (LinkedIn)